Groupama Asset Managment Has $2.24 Million Stock Position in McKesson Corporation $MCK

Groupama Asset Managment reduced its holdings in McKesson Corporation (NYSE:MCK) by 21.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,589 shares of the company’s stock after selling 714 shares during the period. Groupama Asset Managment’s holdings in McKesson were worth $2,240,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of McKesson in the fourth quarter worth approximately $25,000. Swiss RE Ltd. acquired a new stake in shares of McKesson during the fourth quarter worth approximately $26,000. State of Wyoming purchased a new position in McKesson during the second quarter valued at approximately $29,000. Kingdom Financial Group LLC. acquired a new position in McKesson in the 4th quarter valued at approximately $33,000. Finally, Birchwood Financial Partners Inc. acquired a new position in McKesson in the 4th quarter valued at approximately $33,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at McKesson

In other news, EVP Michele Lau sold 3,550 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $761.09, for a total transaction of $2,701,869.50. Following the completion of the sale, the executive vice president owned 3,247 shares in the company, valued at approximately $2,471,259.23. This represents a 52.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Napoleon B. Rutledge, Jr. sold 133 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $764.00, for a total value of $101,612.00. Following the transaction, the chief accounting officer directly owned 632 shares in the company, valued at approximately $482,848. This represents a 17.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 28,748 shares of company stock valued at $22,262,035. Corporate insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

MCK has been the subject of a number of research reports. Bank of America decreased their target price on shares of McKesson from $1,040.00 to $1,000.00 and set a “buy” rating for the company in a research note on Monday, April 6th. Weiss Ratings downgraded shares of McKesson from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, July 7th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $875.00 price objective on shares of McKesson in a report on Friday, May 8th. Citigroup lifted their price objective on McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Finally, TD Cowen lowered their target price on McKesson from $1,012.00 to $989.00 and set a “buy” rating on the stock in a research note on Tuesday, July 21st. Fourteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $962.67.

McKesson Stock Down 0.9%

NYSE MCK opened at $857.61 on Friday. The stock has a market capitalization of $100.41 billion, a PE ratio of 22.29, a price-to-earnings-growth ratio of 1.41 and a beta of 0.31. The company has a 50 day moving average price of $790.71 and a two-hundred day moving average price of $840.22. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Thursday, May 7th. The company reported $11.69 EPS for the quarter, topping the consensus estimate of $11.56 by $0.13. The company had revenue of $96.30 billion for the quarter, compared to analyst estimates of $101.35 billion. McKesson had a net margin of 1.18% and a negative return on equity of 345.35%. McKesson’s quarterly revenue was up 6.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $10.12 EPS. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. As a group, equities analysts anticipate that McKesson Corporation will post 44.28 EPS for the current year.

McKesson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Shareholders of record on Tuesday, September 1st will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, September 1st. This is a positive change from McKesson’s previous quarterly dividend of $0.82. This represents a $3.76 annualized dividend and a yield of 0.4%. McKesson’s dividend payout ratio (DPR) is currently 8.53%.

Key McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson’s compounding growth remains the primary bullish catalyst. The company delivered strong fiscal 2026 results, raised its outlook, increased its dividend and expanded share repurchases. Its distribution and specialty-pharmaceutical businesses continue to generate substantial free cash flow, which may appeal to investors favoring defensive, cash-rich companies. McKesson’s Compounding Keeps Adding Up
• Neutral Sentiment: Wall Street is focused on estimates for McKesson’s quarter ended June 2026, including operating metrics beyond revenue and earnings. The estimates could influence expectations for the company’s upcoming report, but the article does not identify a new earnings surprise or change in guidance. Curious about McKesson Q1 Performance?
• Neutral Sentiment: Recent market commentary highlights a rotation toward defensive stocks as investors respond to inflation, geopolitical tension and uncertainty over interest rates. McKesson’s healthcare-distribution model and free-cash-flow generation could benefit from that trend, although the broader market backdrop remains unsettled. McKesson’s Compounding Keeps Adding Up
• Negative Sentiment: The latest reported quarter offered a mixed signal: adjusted earnings exceeded expectations, but revenue fell short of consensus despite year-over-year growth. That result, combined with a valuation near 22 times earnings and the absence of a fresh company-specific catalyst, may be encouraging profit-taking after the stock’s strong advance.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.